Suchergebnisse

BACKGROUND AND PURPOSE: The impact of weight loss and anatomical change during head and neck (H&N) radiotherapy on spinal cord dosimetry is poorly understood, limiting evidence-based adaptive management strategies. MATERIALS AND METHODS: 133 H&N patients treated with daily mega-voltage CT image-guidance (MVCT-IG) on TomoTherapy, were selected. Elastix software was used to deform planning scan SC contours to MVCT-IG scans, and accumulate dose. Planned (DP) and delivered (DA) spinal cord D2% (SCD2%) were compared. Univariate relationships between neck irradiation strategy (unilateral vs bilateral), T-stage, N-stage, weight loss, and changes in lateral separation (LND) and CT slice surface area (SSA) at C1 and the superior thyroid notch (TN), and ΔSCD2% [(DA - DP) D2%] were examined. RESULTS: The mean value for (DA - DP) D2% was -0.07 Gy (95%CI -0.28 to 0.14, range -5.7 Gy to 3.8 Gy), and the mean absolute difference between DP and DA (independent of difference direction) was 0.9 Gy (95%CI 0.76-1.04 Gy). Neck treatment strategy (p = 0.39) and T-stage (p = 0.56) did not affect ΔSCD2%. Borderline significance (p = 0.09) was seen for higher N-stage (N2-3) and higher ΔSCD2%. Mean reductions in anatomical metrics were substantial: weight loss 6.8 kg; C1LND 12.9 mm; C1SSA 12.1 cm2; TNLND 5.3 mm; TNSSA 11.2 cm2, but no relationship between weight loss or anatomical change and ΔSCD2% was observed (all r2 < 0.1). CONCLUSIONS: Differences between delivered and planned spinal cord D2% are small in patients treated with daily IG. Even patients experiencing substantial weight loss or anatomical change during treatment do not require adaptive replanning for spinal cord safety. ; - The VoxTox project received a 5-year programme grant from Cancer Research UK (CRUK) (Ref: C8857/A13405). - KH, MR and AMB were supported by the programme grant. - DJN is supported by a CRUK Clinical Research Fellowship (Ref: C20/A20917). - PLY and SYKS were supported by the Singapore Government. - LEAS is supported by the University of Cambridge W D Armstrong Trust Fund. - NGB was supported by the NIHR Cambridge Biomedical Research Centre.

The VoxTox research programme has applied expertise from the physical sciences to the problem of radiotherapy toxicity, bringing together expertise from engineering, mathematics, high energy physics (including the Large Hadron Collider), medical physics and radiation oncology. In our initial cohort of 109 men treated with curative radiotherapy for prostate cancer, daily image guidance computed tomography (CT) scans have been used to calculate delivered dose to the rectum, as distinct from planned dose, using an automated approach. Clinical toxicity data have been collected, allowing us to address the hypothesis that delivered dose provides a better predictor of toxicity than planned dose. ; JES was supported by Cancer Research UK through the Cambridge Cancer Centre. NGB, ASP and MG are supported by the National Institute of Health Research Cambridge Biomedical Research Centre. KH, MR AMB, EW and SJB were supported by the VoxTox Research Programme, funded by Cancer Research UK. DJN is supported by Addenbrooke's Charitable Trust and Cancer Research UK through the Cambridge Cancer Centre. FMB was supported by the Science and Technology Facilities Council. MPDS was part supported by the VoxTox Research Programme, funded by Cancer Research UK. RJ was part supported by the VoxTox Research Programme, funded by Cancer Research UK. LS is supported by the Armstrong Trust. XC was supported by the Isaac Newton Trust. CBS acknowledges support from the EPSRC Centre for Mathematical and Statistical Analysis of Multimodal Clinical Imaging, the Leverhulme Trust, the EU-RISE project CHiPS and the Cantab Capital Institute for the Mathematics of Information. NT was supported by a Gates-Cambridge Scholarship, funded by the Bill and Melinda Gates Foundation, PLY and SYKS by the Singapore Government.